Esperion Therapeutics (NASDAQ:ESPR) will announce its Q2 2019 earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($1.86) per share for the quarter.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share for the quarter, beating the consensus estimate of $0.64 by $2.43. The firm had revenue of $145.42 million during the quarter, compared to analyst estimates of $69.35 million. During the same period in the previous year, the firm posted ($1.73) EPS. On average, analysts expect Esperion Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of ESPR stock opened at $37.82 on Tuesday. The company has a 50-day moving average price of $45.20. Esperion Therapeutics has a twelve month low of $36.06 and a twelve month high of $60.99. The firm has a market cap of $1.01 billion, a P/E ratio of -5.02 and a beta of 1.67.
Several research analysts recently weighed in on ESPR shares. Northland Securities set a $65.00 target price on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Friday, June 14th. Credit Suisse Group boosted their target price on shares of Esperion Therapeutics from $79.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, May 6th. BidaskClub downgraded shares of Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 31st. Stifel Nicolaus reissued a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 13th. Finally, Goldman Sachs Group downgraded shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 target price for the company. in a research note on Wednesday, May 29th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $74.00.
In other Esperion Therapeutics news, major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction on Tuesday, July 23rd. The stock was bought at an average price of $42.65 per share, for a total transaction of $2,132,500.00. Following the acquisition, the insider now directly owns 3,572,964 shares of the company’s stock, valued at $152,386,914.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Timothy M. Mayleben purchased 5,000 shares of the stock in a transaction on Friday, June 28th. The stock was acquired at an average price of $46.00 per share, with a total value of $230,000.00. Following the acquisition, the chief executive officer now directly owns 66,163 shares in the company, valued at $3,043,498. The disclosure for this purchase can be found here. Insiders acquired a total of 60,000 shares of company stock valued at $2,560,300 in the last 90 days. 7.70% of the stock is owned by company insiders.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: Hedge Funds
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.